Twinbeech Capital LP Editas Medicine, Inc. Transaction History

Twinbeech Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $984,643 - $1.57 Million	80,974 New	80,974 $991,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $987,235 - $1.51 Million	-37,184 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $1.46 Million - $2.71 Million	37,184 New	37,184 $1.53 Million
Q2 2021 Aug 16, 2021	SELL	$31.29 - $56.64 $392,689 - $710,832	-12,550 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $498,360 - $1.14 Million	12,550 New	12,550 $527,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.